

Rozanolixizumab-noli (Rystiggo) Patient Referral Form

Admissions Fax # 844-878-6917

Admissions Phone # 855-WE-R-RARE (855-937-7273)

Patient Demographi	cs Information			Admission	13 I HOHE # 655 WE	11 11/11/11	_ (033 3	37 72	, 5,		
Patient Demographics Information Patient Name						SSN#			DOB		
Patient Address						•					
Primary Phone			Cellular Phone			Work Ph	Work Phone				
Emergency Contact Name, Relationship				En			mergency Contact Phone Number				
Additional Documen	tation Needed	t									
- Copy of insurance cards - History and Phys - Patient face sheet w/demographics - Antibody testing								r/diff, BMP, & CMP t vitals including blood pressure			
Patient Insurance Inf	ly testing results	- Necent vitais including blood pressure									
Insurance Plan #1					Insurance Plan #2						
Plan Address				Plan Address							
Plan Phone & Fax Numbers					Plan Phone & Fax Numbers						
Subscriber Name			DOB Subscriber Name				DOB				
Policy Number Group II		Group ID	1	Policy Number				Group ID			
Patient Clinical Infor	mation										
Gender Height (in		lbs.)	Allergies	(food/drug)							
□M □F											
Statement of Medica				osis							
ICD10:	Descript	ion of diag	nosis:				Current M	G-ADL Sco	ore:		
Medication Informat	tion / Prescrip	tion and	d Order	S							
Medication: Quantity/Refills											
		nechanical	syringe pi	ump at a rate of up t	o 20 mL/hr		Dispense:	,,			
Rystiggo	per manufacturer		, , ,		•		I '	pply, refill	l x12mo. l	Jnless otherwise	
1 00 - 1							noted □ Other				
< 50 kg											
\square 420 mg (3 mL) SubQ every week for 6 weeks. 50-99 kg							*If subsequent treatment cycles only				
☐ 560 mg (4 mL) SubQ every week for 6 weeks.							Start date of last cycle:				
≥100 kg									-,		
0, ,	ubQ every week for	6 weeks.									
Premedications			:	- diad)						ity/Refills	
☐ Give premedication(s) 30 minutes prior to infusion (<i>generics will be dispensed</i>) Diphenhydramine ☐ 25-50 mg PO									Dispense:		
Diphenhydramine ☐ 25-50 mg PO Fexofenadine ☐ 180 mg PO										#QS + PRN refills nerwise noted	
Acetaminophen									☐ Other		
☐ Lidocaine 2.5% and prilocaine 2.5% (EMLA) topical cream: apply to SQ needle site prior to access PRN pain upon needle insertion.											
□ RN to instruct patient to hydrate pre/post infusion.											
□ Other											
Adverse Reaction Or	dors										
Adverse Reaction Orders In the event of an infusion reaction (i.e. fever, chills, backache, headache, rigors, etc.) the following order will be followed											
and the ordering provider will be notified:											
- Mild reaction: Pause infusion and administer diphenhydramine 50 mg PO x1 dose. If needed, give an additional dose of											
diphenhydramine 50 mg PO x1 dose. Max 2 doses. Resume infusion once symptoms resolve. - Moderate reaction: Stop infusion and administer diphenhydramine 50 mg PO x1 dose.											
- Noderate reaction. Stop initision and administer dipliently draftine 50 flig PO X1 dose. - Severe reaction (w/breathing problems): CALL 911, administer epinephrine 0.3 mg IM. #QS + PRN refills											
Prescriber Information											
Prescriber Name Office Contact											
Practice Address						Practice Phone					
NPI# License #						Practice Fax					
Physician Signature Required - Substitution Permitted Date Physician Signature R						d - Dispense as Written Date					